REGULATORY SERVICES
Achieving Zero FDA Deficiencies and $1.9M+ in Cost Avoidance Across 160 Deliverables for a Global Anesthesia Device Leader
Consultant: Jaani Gandhi
EU MDR 2017/745 Annex XIV
MEDDEV 2.7/1 Rev 4
Our Results
Deliverables
Resolved
THE PRODUCTS
Anesthesia & Patient Monitoring
A global medical device company whose anesthesia and patient monitoring division operates at $8B in revenue, supplying life-critical devices to healthcare systems worldwide.
THE CHALLENGE
A Compliance Program Built on a Minimal Foundation
The business unit entered the engagement managing 40 product families with a post-market surveillance infrastructure built for a prior regulatory era — documents existed, but lacked the clinical rigor required under MDR.
What followed was a compounding problem: initial documentation gaps triggered recurring deficiencies, and without a system to absorb and apply audit feedback, each maintenance cycle created new exposure rather than closing it.
The core liability wasn't bandwidth - it was a revolving door of nine contributors who lacked the clinical depth to write defensible post-market surveillance documentation under MDR scrutiny.
With each round of Notified Body or FDA deficiencies carrying a $10K–$50K remediation cost (on resources), and repeated failures risking device removal from market, the program needed both immediate execution and a durable system to prevent recurring audit exposure.
THE APPROACH
Rebuilding from the Ground Up
To address this, we focused on rebuilding the documentation program from the ground up while simultaneously absorbing and resolving active deficiency backlogs — with an emphasis on eliminating audit risk at the source.
Key elements of the approach included:
Rapid clinical domain mastery per product family — enabling defensible literature review and safety/performance evaluation without extended onboarding cycles
Deficiency tracker infrastructure — a cross-program system ensuring every prior Notified Body or FDA remark was embedded into future document templates, structurally preventing repeat findings
Cross-functional alignment as a compliance lever — bridging engineering, clinical, and regulatory stakeholders to accelerate review cycles and resolve queries without rework loops.
This allowed the team to move from reactive deficiency response to a proactive compliance posture across the entire program.
THE OUTCOME
From Audit Risk to Compliance Anchor
The client emerged with zero FDA deficiencies across all owned projects and a single Notified Body deficiency across 76 audit cycles.
Beyond the metrics, the engagement transformed an unstable, high-turnover documentation function into a governed, repeatable process. With the deficiency tracker embedded into ongoing workflows, each future project iteration carries less audit exposure than the last — compounding cost and time savings well beyond the engagement itself.
Facing a similar challenge?
Whether you’re pre-market, sustaining, or facing a mountain of deficiencies, having the right clinical strategy and structure in place makes all the difference. Let’s talk about where you are, what’s getting in the way, and how to create momentum.